Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

The Food and Drug Administration on Friday said the shortage of Novo Nordisk's weight-loss and diabetes drugs Wegovy and Ozempic is resolved, a move that could limit the availability of cheaper ...

Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared ...

Delivery apps are allowing Chinese citizens to get their hands on the popular weight-loss and diabetes drugs at the touch of ...

The number of teens and young adults taking GLP-1 drugs has increased by 594 percent—but scientists are still trying to ...

The FDA has declared that the shortage of popular weight-loss drugs, including Ozempic and Wegovy, is officially over.

Feb 21 (Reuters) - The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's ...

Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...

Wegovy is a brand-name subcutaneous injection prescribed for weight loss and reduction of cardiovascular risks. Its cost with and without insurance can depend on several factors, such as whether ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

Wegovy (semaglutide) is a prescription drug used for weight loss and to lower risk of cardiovascular problems. The drug comes as a liquid solution for injection under your skin. It’s usually ...